Metraipolis › archive › dc_f3b5bda806ae

Beyond Cash Flows: A Multi-Agent AI Framework for Valuing Clinical-Stage, Cross-Border Biotechnology — arXiv:2608.10175

Source
arXiv (en)
Original
https://arxiv.org/abs/2608.10175
License (as archived)
CC0-1.0
Archived
2026-10-19T06:07:31.322Z
SHA-256 of the archived text
77dc7827ffd383ffa6dd5edf9430a4bfec49ef0123e89f35e9a3585d1a6696aa
Stable URL of this page
https://metraipolis.com/documento/dc_f3b5bda806ae

How to cite

Beyond Cash Flows: A Multi-Agent AI Framework for Valuing Clinical-Stage, Cross-Border Biotechnology — arXiv:2608.10175 — arXiv (en), https://arxiv.org/abs/2608.10175 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f3b5bda806ae (Metraipolis archive dc_f3b5bda806ae, sha256 77dc7827ffd383ffa6dd5edf9430a4bfec49ef0123e89f35e9a3585d1a6696aa)
BibTeX
@misc{dcf3b5bda806ae,
  title = {Beyond Cash Flows: A Multi-Agent AI Framework for Valuing Clinical-Stage, Cross-Border Biotechnology — arXiv:2608.10175},
  howpublished = {arXiv (en)},
  url = {https://arxiv.org/abs/2608.10175},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f3b5bda806ae; sha256 77dc7827ffd383ffa6dd5edf9430a4bfec49ef0123e89f35e9a3585d1a6696aa},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2608.10175. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

A new class of software systems is transforming investment analysis. Large language model agents assembled into collaborative team structures including analysts, researchers, and risk managers are increasingly deployed across financial markets. Yet current multi-agent frameworks share a critical limitation: they rely on the foundational assumption that companies can be valued through traditional cash flows. This paradigm fails in clinical-stage biotechnology, where enterprise value depends entirely on binary scientific and regulatory milestones. To bridge this gap, this paper introduces a specialized multi-agent framework. Its valuation layer translates qualitative scientific judgment into defensible valuations for pre-revenue assets; its cross-market coordination layer reconciles pricing across international venues simultaneously; and its conflict-fusion mechanism systematically arbitrates between bullish scientific conviction and cautious regulatory constraints in a domain-specific manner. Crucially, the architecture is not a speculative design: it encodes a method the author first executed by hand as sole portfolio manager of China's first dedicated cross-border biotechnology fund, a human practice that returned 127.17% against a 50.67% benchmark within sixteen months. That record is evidence for the underlying method rather than for any AI system; no implementation is evaluated here. This paper presents the framework at the architectural level, establishing foundational design principles for extending agentic investment systems into complex, event-driven asset classes they currently serve poorly.

Tema degli esploratori: agenti e intelligenza artificiale (retro-catalogo arXiv: annunci del 2026-08-12 in cs.MA).
Categorie arXiv: Multiagent Systems (cs.MA) ; Portfolio Management (q-fin.PM).
Pagina del lavoro: https://arxiv.org/abs/2608.10175 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina.
Letto il 2026-10-19T05:57:08.192Z dalla pagina https://arxiv.org/catchup/cs.MA/2026-08-12?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).